Literature DB >> 23750489

Risk of oral antifungal agent-induced liver injury in Taiwanese.

Wei-Yu Kao1, Chien-Wei Su, Yi-Shin Huang, Yueh-Ching Chou, Yi-Chih Chen, Wen-Hung Chung, Ming-Chih Hou, Han-Chieh Lin, Fa-Yauh Lee, Jaw-Ching Wu.   

Abstract

AIM: Oral antifungal agent-induced liver injury is a common safety concern that may lead to patients' hesitation in treating fungal infections such as onychomycosis. This study evaluated risk of drug-induced liver injury (DILI) caused by oral antifungal agents in Taiwanese populations.
METHODS: A population-based study was conducted by analyzing who used oral antifungal agents from 2002 to 2008 from the Taiwan National Health Insurance Database. A comparison control group was randomly extracted from the remainder of the original cohort.
RESULTS: Of the 90,847 oral antifungal agents users, 52 patients had DILI. Twenty-eight DILI cases used ketoconazole, 12 fluconazole, eight griseofulvin, three itraconazole and two terbinafine. The incidence rates (IR) of DILI per 10,000 persons were 31.6, 4.9, 4.3, 3.6 and 1.6 for fluconazole, ketoconazole, griseofulvin, itraconazole and terbinafine, respectively. Longer exposure duration increased the risk of DILI, with IR for exposure duration ≥ 60 defined daily dose (DDD) of 170.9, 62.5, and 36.1 per 10,000 persons for ketoconazole, itraconazole and terbinafine, respectively. Patients taking antifungal agents had higher incidences of developing DILI compared with those in the control group after adjusting for age, gender and co-morbidities (relative risk 2.38, P < 0.001). All of the six patients with fatal DILI used fluconazole. Old age and fluconazole increased the risk of oral antifungal-induced fatal DILI.
CONCLUSIONS: Oral antifungal agents are associated with low incidence of acute liver injury, but which may be fatal, especially for the elderly. Longer treatment duration may increase the risk of antifungal agent-induced liver injury, especially ketoconazole.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  Taiwanese; drug-induced liver injury; hepatitis; oral antifungal agents

Mesh:

Substances:

Year:  2014        PMID: 23750489      PMCID: PMC3895359          DOI: 10.1111/bcp.12178

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  37 in total

1.  Safety of newly approved drugs: implications for prescribing.

Authors:  Robert J Temple; Martin H Himmel
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

2.  The effect of age upon liver volume and apparent liver blood flow in healthy man.

Authors:  H A Wynne; L H Cope; E Mutch; M D Rawlins; K W Woodhouse; O F James
Journal:  Hepatology       Date:  1989-02       Impact factor: 17.425

3.  Terbinafine-induced hepatic failure requiring liver transplantation.

Authors:  Zeeshan Perveze; Mark W Johnson; Raymond A Rubin; Marty Sellers; Carlos Zayas; Jody L Jones; Rosemary Cross; Kimberly Thomas; Bradley Butler; Roshan Shrestha
Journal:  Liver Transpl       Date:  2007-01       Impact factor: 5.799

4.  Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis.

Authors:  Jiing-Chyuan Luo; Hsin-Bang Leu; Kuang-Wei Huang; Chin-Chou Huang; Ming-Chih Hou; Han-Chieh Lin; Fa-Yauh Lee; Shou-Dong Lee
Journal:  CMAJ       Date:  2011-11-14       Impact factor: 8.262

5.  Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan.

Authors:  Sheng-Nan Lu; Wei-Wen Su; Sheng-Shun Yang; Ting-Tsung Chang; Ken-Sheng Cheng; Jaw-Ching Wu; Hans Hsienhong Lin; Shun-Sheng Wu; Chuan-Mo Lee; Chi-Sin Changchien; Chien-Jen Chen; Jin-Chuan Sheu; Ding-Shinn Chen; Chien-Hung Chen
Journal:  Int J Cancer       Date:  2006-10-15       Impact factor: 7.396

6.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.

Authors:  Adrian Reuben; David G Koch; William M Lee
Journal:  Hepatology       Date:  2010-10-14       Impact factor: 17.425

Review 7.  Hepatotoxicity of antifungal agents.

Authors:  Jessica C Song; Stanley Deresinski
Journal:  Curr Opin Investig Drugs       Date:  2005-02

Review 8.  Review article: drug hepatotoxicity.

Authors:  C Y Chang; T D Schiano
Journal:  Aliment Pharmacol Ther       Date:  2007-05-15       Impact factor: 8.171

Review 9.  Epidemiology of idiosyncratic drug-induced liver injury.

Authors:  Lauren N Bell; Naga Chalasani
Journal:  Semin Liver Dis       Date:  2009-10-13       Impact factor: 6.115

10.  Risk of liver injury associated with Chinese herbal products containing radix bupleuri in 639,779 patients with hepatitis B virus infection.

Authors:  Chang-Hsing Lee; Jung-Der Wang; Pau-Chung Chen
Journal:  PLoS One       Date:  2011-01-12       Impact factor: 3.240

View more
  16 in total

Review 1.  Oral antifungal medication for toenail onychomycosis.

Authors:  Sanne Kreijkamp-Kaspers; Kate Hawke; Linda Guo; George Kerin; Sally Em Bell-Syer; Parker Magin; Sophie V Bell-Syer; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2017-07-14

2.  The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine.

Authors:  Robert John Fontana; Elizabeth Theresa Cirulli; Jiezhun Gu; David Kleiner; David Ostrov; Elizabeth Phillips; Ryan Schutte; Huiman Barnhart; Naga Chalasani; Paul Brent Watkins; Jay H Hoofnagle
Journal:  J Hepatol       Date:  2018-08-21       Impact factor: 25.083

3.  Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Ariola Koci; Paolo Caraceni; Fabrizio De Ponti
Journal:  World J Hepatol       Date:  2014-08-27

4.  Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study.

Authors:  Antonios Douros; Elisabeth Bronder; Frank Andersohn; Andreas Klimpel; Michael Thomae; Giselle Sarganas; Reinhold Kreutz; Edeltraut Garbe
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

5.  Utility of Laboratory Test Result Monitoring in Patients Taking Oral Terbinafine or Griseofulvin for Dermatophyte Infections.

Authors:  Deirdre A Stolmeier; Hannah B Stratman; Thomas J McIntee; Erik J Stratman
Journal:  JAMA Dermatol       Date:  2018-12-01       Impact factor: 10.282

6.  Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up.

Authors:  Yuan-Lung Cheng; Yuan-Jen Wang; Wei-Yu Kao; Ping-Hsien Chen; Teh-Ia Huo; Yi-Hsiang Huang; Keng-Hsin Lan; Chien-Wei Su; Wan-Leong Chan; Han-Chieh Lin; Fa-Yauh Lee; Jaw-Ching Wu
Journal:  PLoS One       Date:  2013-08-22       Impact factor: 3.240

7.  The possible efficacy of artichoke in fluconazole related hepatotoxicity.

Authors:  Hüseyin Kurt; Omer Toprak; Erdoğan Bülbül
Journal:  Case Reports Hepatol       Date:  2014-09-03

8.  Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients.

Authors:  Chih-Chin Kao; Pei-Chen Wu; Che-Hsiung Wu; Li-kwang Chen; Hsi-Hsien Chen; Mai-Szu Wu; Vin-Cent Wu
Journal:  Sci Rep       Date:  2016-01-11       Impact factor: 4.379

9.  Revisiting the Metabolism and Bioactivation of Ketoconazole in Human and Mouse Using Liquid Chromatography-Mass Spectrometry-Based Metabolomics.

Authors:  Ju-Hyun Kim; Won-Gu Choi; Sangkyu Lee; Hye Suk Lee
Journal:  Int J Mol Sci       Date:  2017-03-13       Impact factor: 5.923

10.  Comparative Hepatotoxicity of Fluconazole, Ketoconazole, Itraconazole, Terbinafine, and Griseofulvin in Rats.

Authors:  Star Khoza; Ishmael Moyo; Denver Ncube
Journal:  J Toxicol       Date:  2017-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.